At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Phase I/II Study of Cediranib and Olaparib in Combination for Treatment of Recurrent Papillary-Serous Ovarian, Fallopian Tube, or Peritoneal Cancer or for Treatment of Recurrent Triple-Negative Breast Cancer
In Brief
A Phase 2 clinical trial evaluating Biopsy Procedure, Biospecimen Collection, and 6 other interventions for Fallopian Tube Carcinoma and 6 related conditions. Active but no longer recruiting, targeting 155 participants across 14 sites.
Detailed Summary
This partially randomized phase I/II trial studies the side effects and the best dose of cediranib maleate and olaparib and to see how well they work compared to olaparib alone in treating patients with ovarian, fallopian tube, peritoneal, or triple-negative breast cancer that has returned after a period of improvement (recurrent). Cediranib maleate may help keep cancer cells from growing by affecting their blood supply. Olaparib may stop cancer cells from growing abnormally. The combination of cediranib maleate and olaparib may be safe, tolerable and/or effective in treating patients with recurrent ovarian, fallopian tube, or peritoneal cancer or recurrent triple-negative breast cancer.
Study Details
Timeline
Interventions
Undergo optional tissue biopsy
Undergo blood sample collection
Given PO
Undergo CT
Undergo ECHO
Undergo MRI
Undergo MUGA
Given PO